- Home
- TSBK vs CLLS Comparison
TSBK vs CLLS Comparison
Compare TSBK & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TSBK | CLLS |
|---|---|---|
| Founded | 1915 | 1999 |
| Country | United States | France |
| Employees | N/A | 222 |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 271.5M | 485.6M |
| IPO Year | 1998 | 2007 |
Fundamental Metrics
Financial Performance| Metric | TSBK | CLLS |
|---|---|---|
| Price | $36.13 | $4.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 18.9K | ★ 116.7K |
| Earning Date | 01-26-2026 | 11-07-2025 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | ★ 21.93 | N/A |
| EPS | ★ 3.67 | N/A |
| Revenue | $81,618,000.00 | ★ $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | N/A | $20.68 |
| P/E Ratio | $9.84 | ★ N/A |
| Revenue Growth | 10.07 | ★ 129.04 |
| 52 Week Low | $27.51 | $1.10 |
| 52 Week High | $38.28 | $5.48 |
Technical Indicators
Market Signals| Indicator | TSBK | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 55.98 | 56.30 |
| Support Level | $35.98 | $4.47 |
| Resistance Level | $38.28 | $5.45 |
| Average True Range (ATR) | 1.12 | 0.29 |
| MACD | -0.13 | -0.03 |
| Stochastic Oscillator | 56.57 | 60.39 |
Price Performance
Historical ComparisonAbout TSBK Timberland Bancorp Inc.
Timberland Bancorp Inc is a bank holding company. It has one reportable operating segment which is defined as community banking in western Washington under the operating name Timberland Bank. The bank offers a variety of services such as checking accounts, online and mobile banking, savings accounts, home loans, consumer loans, construction loans, business rewards, cash management, small business solutions, and business checking accounts among others. It also offers loans to real estate, including residential and commercial, multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans, and land loans.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.